SCHEDULE 13G/A: Casdin Capital and Eli Casdin Disclose 3.7% Stake in Century Therapeutics

Casdin Capital, LLC and Eli Casdin have filed an amended Schedule 13G, revealing a shared beneficial ownership of 3.7% in Century Therapeutics, Inc.'s common stock as of March 31, 2025.

Summary

• Casdin Capital, LLC and Eli Casdin jointly filed an Amendment No. 1 to Schedule 13G regarding their beneficial ownership in Century Therapeutics, Inc.
• The filing indicates that as of March 31, 2025, both Casdin Capital, LLC and Eli Casdin beneficially own 3,212,316 shares of Century Therapeutics, Inc. Common Stock.
• This aggregate amount represents 3.7% of the outstanding class of Century Therapeutics, Inc. Common Stock.
• Both reporting persons have shared voting power and shared dispositive power over all 3,212,316 shares.
• Casdin Capital, LLC is classified as an Investment Adviser (IA), and Eli Casdin is classified as a Parent Holding Company (HC) and Individual (IN).
• The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.
• The shares are directly owned by advisory clients of Casdin Capital, LLC, with no single client beneficially owning more than 5% of the Common Stock.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership and does not inherently convey positive or negative sentiment regarding the company's performance or outlook. It simply reports a change in ownership percentage.

Future Outlook

The document is a disclosure of beneficial ownership and does not contain any forward-looking statements or guidance regarding Century Therapeutics, Inc.'s future performance or operations.

Industry Context

This filing is a standard disclosure of passive ownership by an investment firm and its principal in a publicly traded biotechnology company. It reflects an investment position rather than a strategic industry move or operational update. The 3.7% stake indicates a significant, but non-controlling, investment in Century Therapeutics, a company operating in the biotechnology sector.

Stakeholder Impact

• Shareholders: The disclosure of a significant, albeit passive, stake by Casdin Capital and Eli Casdin provides transparency regarding the ownership structure of Century Therapeutics, Inc. This information can be relevant for other investors assessing the company's shareholder base and institutional interest.

Key Dates

Keywords

Century Therapeutics, Casdin Capital, Eli Casdin, Schedule 13G/A, Beneficial Ownership, Common Stock, SEC Filing, Investment Adviser, Biotechnology, Healthcare